Pharmacogenetics in early drug development for non-alcoholic steatohepatitis: missed chances and future opportunities

Amangurbanova M, Huang DQ, Loomba R (2023) Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. Aliment Pharmacol Ther 57:37–51. https://doi.org/10.1111/apt.17292

Article  CAS  PubMed  Google Scholar 

Boeckmans J, Natale A, Rombaut M et al (2020) Anti-NASH drug development hitches a lift on PPAR agonism. Cells 9:1–20. https://doi.org/10.3390/cells9010037

Article  CAS  Google Scholar 

Boeckmans J, Natale A, Rombaut M et al (2021) Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. Cell Biol Toxicol 37:293–311. https://doi.org/10.1007/s10565-020-09544-2

Article  CAS  PubMed  Google Scholar 

Boeckmans J, Gatzios A, Schattenberg JM et al (2023) PNPLA3 I148M and response to treatment for hepatic steatosis: a systematic review. Liver Int. https://doi.org/10.1111/liv.15533

Article  PubMed  Google Scholar 

Cherubini A, Casirati E, Tomasi M, Valenti L (2021) PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets 25:1033–1043. https://doi.org/10.1080/14728222.2021.2018418

Article  CAS  PubMed  Google Scholar 

De Vincentis A, Tavaglione F, Jamialahmadi O et al (2022) A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. Clin Gastroenterol Hepatol 20:658–673. https://doi.org/10.1016/j.cgh.2021.05.056

Article  CAS  PubMed  Google Scholar 

Dongiovanni P, Stender S, Pietrelli A et al (2018) Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med 283:356–370. https://doi.org/10.1111/joim.12719

Article  CAS  PubMed  Google Scholar 

Drenth JPH, Schattenberg JM (2020) The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Expert Opin Investig Drugs 29:1365–1375. https://doi.org/10.1080/13543784.2020.1839888

Article  CAS  PubMed  Google Scholar 

Eslam M, George J (2020) Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol 17:40–52. https://doi.org/10.1038/s41575-019-0212-0

Article  PubMed  Google Scholar 

Eslam M, Sanyal AJ, George J et al (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158:1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312

Article  CAS  PubMed  Google Scholar 

Friedman SL, Ratziu V, Harrison SA et al (2018) A Randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67:1754–1767. https://doi.org/10.1002/hep.29477

Article  CAS  PubMed  Google Scholar 

Gatzios A, Rombaut M, Buyl K et al (2022) From NAFLD to MAFLD: aligning translational in vitro research to clinical insights. Biomedicines 10:1–19. https://doi.org/10.3390/biomedicines

Article  Google Scholar 

Gawrieh S, Guo X, Tan J et al (2019) A pilot genome-wide analysis study identifies loci associated with response to obeticholic acid in patients with NASH. Hepatol Commun 3:1571–1584. https://doi.org/10.1002/hep4.1439

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harrison SA, Allen AM, Dubourg J et al (2023) Challenges and opportunities in NASH drug development. Nat Med 29:562–573. https://doi.org/10.1038/s41591-023-02242-6

Article  CAS  PubMed  Google Scholar 

Kawaguchi-Suzuki M, Cusi K, Bril F et al (2018) A genetic score associates with pioglitazone response in patients with non-alcoholic steatohepatitis. Front Pharmacol 9:752. https://doi.org/10.3389/fphar.2018.00752

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mantovani A, Scorletti E, Mosca A et al (2020) Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 111S:154170. https://doi.org/10.1016/j.metabol.2020.154170

Article  CAS  PubMed  Google Scholar 

Powell NR, Liang T, Ipe J et al (2023) Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease. Nat Commun 14:1474. https://doi.org/10.1038/s41467-023-37209-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramos MJ, Bandiera L, Menolascina F, Fallowfield JA (2022) In vitro models for non-alcoholic fatty liver disease: emerging platforms and their applications. iScience 25:103549. https://doi.org/10.1016/j.isci

Article  PubMed  Google Scholar 

Romeo S, Kozlitina J, Xing C et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465. https://doi.org/10.1038/ng.257.Genetic

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schattenberg JM, Lazarus JV, Newsome PN et al (2021) Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis. Liver Int 41:1227–1242. https://doi.org/10.1111/liv.14825

Article  PubMed  PubMed Central  Google Scholar 

Vandel J, Dubois-Chevalier J, Gheeraert C et al (2020) Hepatic molecular signatures highlight the sexual dimorphism of Non-Alcoholic SteatoHepatitis (NASH). Hepatology 73:920–936. https://doi.org/10.1002/hep.31312

Article  CAS  PubMed  Google Scholar 

Yang L, Hao Y, Boeckmans J et al (2023) Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: novel therapeutic targets. Pharmacol Ther 243:108353. https://doi.org/10.1016/j.pharmthera.2023.108353

Article  CAS  PubMed  Google Scholar 

Yip TCF, Vilar-Gomez E, Petta S et al (2022) Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology 77:1404–1427. https://doi.org/10.1002/hep.32774

Article  PubMed  Google Scholar 

Younossi ZM, Golabi P, Paik JM et al (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77:1335–1347. https://doi.org/10.1097/HEP.0000000000000004

Article  PubMed  Google Scholar 

Zhou H-H, Liu Z-Q (2000) Ethnic differences in drug metabolism. Clin Chem Lab Med 38:899–903. https://doi.org/10.1515/CCLM.2000.131

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif